Blue Trust Inc. Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Blue Trust Inc. raised its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1,705.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,997 shares of the biopharmaceutical company’s stock after buying an additional 2,831 shares during the quarter. Blue Trust Inc.’s holdings in Amicus Therapeutics were worth $30,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in FOLD. Assenagon Asset Management S.A. purchased a new stake in shares of Amicus Therapeutics during the 2nd quarter worth about $8,386,000. M&G Plc grew its holdings in shares of Amicus Therapeutics by 12.4% during the 2nd quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after purchasing an additional 82,728 shares during the period. Edgestream Partners L.P. grew its holdings in shares of Amicus Therapeutics by 1,290.4% during the 1st quarter. Edgestream Partners L.P. now owns 270,164 shares of the biopharmaceutical company’s stock worth $3,183,000 after purchasing an additional 250,734 shares during the period. CANADA LIFE ASSURANCE Co grew its holdings in shares of Amicus Therapeutics by 7.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock worth $1,183,000 after purchasing an additional 7,304 shares during the period. Finally, Fiera Capital Corp grew its holdings in shares of Amicus Therapeutics by 1.1% during the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock worth $52,382,000 after purchasing an additional 58,113 shares during the period.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $11.47 on Friday. The business’s 50 day moving average is $11.15 and its two-hundred day moving average is $10.59. Amicus Therapeutics, Inc. has a 52-week low of $9.02 and a 52-week high of $14.57. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The company had revenue of $126.67 million for the quarter, compared to analyst estimates of $121.21 million. During the same period in the prior year, the company posted ($0.15) EPS. Amicus Therapeutics’s quarterly revenue was up 34.0% on a year-over-year basis. As a group, equities research analysts predict that Amicus Therapeutics, Inc. will post -0.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on FOLD shares. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. Morgan Stanley decreased their price target on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, October 11th. JPMorgan Chase & Co. decreased their price target on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. Bank of America upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a report on Friday, September 20th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.13.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,398,532.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.20% of the stock is currently owned by corporate insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.